Rationale and design of a randomized, controlled multicentre clinical trial to evaluate the effect of bromocriptine on left ventricular function in women with peripartum cardiomyopathy
Authors:
Open Access
- 31 May 2015
- journal article
- research article
- Published by Springer Nature in Clinical Research in Cardiology
- Vol. 104 (11) , 911-917
Abstract
Background Peripartum cardiomyopathy (PPCM) is an idiopathic heart disease that develops in the last month of pregnancy and/or the first months following delivery in previously healthy women and may lead to acute heart failure. A cleaved fragment of the nursing hormone prolactin is considered essential in the pathophysiology of PPCM. To date, no specific therapy has been tested for PPCM in a randomized controlled trial of adequate size. Aims The purpose of this trial is to investigate the safety of the dopamin-D2-receptor agonist bromocriptine and its effects on left ventricular (LV) function in women with PPCM. Methods This is an 11 center German trial with a prospective randomized controlled open-label design. The trial enrolls females with newly diagnosed PPCM according to European Society of Cardiology criteria with a LV ejection fraction (LVEF) <35 %. Patients are randomized 1:1 to either best supportive care (BSC) including standard heart failure therapy plus 8 weeks of bromocriptine therapy (2.5 mg b.i.d. for 14 days and 2.5 mg q.d. from day 15 to 56) or to BSC plus 1 week of low-dose bromocriptine (2.5 mg q.d.) with anticoagulant therapy at a prophylactic dose administered during the period of bromocriptine treatment in both groups. The primary endpoint is change in LVEF from baseline to 6 months follow-up as assessed by cardiac magnetic resonance imaging (or echocardiography if CMR is not tolerated). The secondary endpoints are hospitalization for worsening heart failure, heart transplantation, and all-cause mortality during follow-up or a combination of these endpoints. A total of 60 patients will be recruited (including 6 potential dropouts) giving a power of 0.9 for an expected LVEF change of 10.8 % between treatment groups at 6 months. Perspective This trial will provide important knowledge on potential benefits and safety of prolonged inhibition of prolactin release with bromocriptine in addition to standard heart failure therapy in newly diagnosed PPCM. Trial registration: ClinicalTrials.gov Identifier: NCT00998556.Keywords
Funding Information
- German Federal Ministry of Education and Research (BMBF)
- „Junge Akademie“ programme of Hannover Medical School
This publication has 26 references indexed in Scilit:
- Tailoring diuretic therapy in acute heart failure: insight into early diuretic response predictorsClinical Research in Cardiology, 2013
- Phenotyping and outcome on contemporary management in a German cohort of patients with peripartum cardiomyopathyBasic Research in Cardiology, 2013
- MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathyJournal of Clinical Investigation, 2013
- ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012European Journal of Heart Failure, 2012
- Aliskiren, ALTITUDE, and the Implications for ATMOSPHEREEuropean Journal of Heart Failure, 2012
- Evaluation of Bromocriptine in the Treatment of Acute Severe Peripartum CardiomyopathyCirculation, 2010
- A Cathepsin D-Cleaved 16 kDa Form of Prolactin Mediates Postpartum CardiomyopathyCell, 2007
- Haemostatic changes in pregnancyThrombosis Research, 2004
- Underlying Causes and Long-Term Survival in Patients with Initially Unexplained CardiomyopathyNew England Journal of Medicine, 2000
- The safety of bromocriptine in long-term use: a review of the literatureCurrent Medical Research and Opinion, 1986